Vertex Sits On $1.4bn Cash, Seeks External Innovation Away From CF
Vertex – a company currently leading the lucrative cystic fibrosis market and set to retain command of this arena into the foreseeable future – is preparing to replicate its CF success in another therapy area.
You may also be interested in...
Vertex continued its growth story in cystic fibrosis during 2017. It also chose a pair of candidates for Phase III triple combination development, threatening to virtually seal off market entry to others.
VC Playbook: The fundamentals do not change in life sciences investing – good science, unmet need and social responsibility.
The biopharma industry broke records again in 2021 with the amount of money raised for drug development. After a year of rapid growth, what will 2022 bring for market dynamics and R&D catalysts in biopharma?